These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


3847 related items for PubMed ID: 28230005

  • 1. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K, Yuan Q.
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [Abstract] [Full Text] [Related]

  • 2. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS, Cho BC, Soo RA.
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [Abstract] [Full Text] [Related]

  • 3. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D, Santini S, Cardinali B, Papoff G, Lalli C, Samperna S, Fustaino V, Giannini G, Ruberti G.
    PLoS One; 2015 Mar; 10(11):e0143333. PubMed ID: 26580964
    [Abstract] [Full Text] [Related]

  • 4. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
    Liao BC, Lin CC, Lee JH, Yang JC.
    Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
    [Abstract] [Full Text] [Related]

  • 5. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
    Zhou J, Wang J, Zeng Y, Zhang X, Hu Q, Zheng J, Chen B, Xie B, Zhang WM.
    Oncotarget; 2015 Dec 29; 6(42):44332-45. PubMed ID: 26554308
    [Abstract] [Full Text] [Related]

  • 6. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
    Nurwidya F, Takahashi F, Murakami A, Kobayashi I, Kato M, Shukuya T, Tajima K, Shimada N, Takahashi K.
    Respir Investig; 2014 Mar 29; 52(2):82-91. PubMed ID: 24636263
    [Abstract] [Full Text] [Related]

  • 7. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.
    Lung Cancer; 2015 Sep 29; 89(3):357-9. PubMed ID: 26187428
    [Abstract] [Full Text] [Related]

  • 8. SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer.
    Della Corte CM, Bellevicine C, Vicidomini G, Vitagliano D, Malapelle U, Accardo M, Fabozzi A, Fiorelli A, Fasano M, Papaccio F, Martinelli E, Troiani T, Troncone G, Santini M, Bianco R, Ciardiello F, Morgillo F.
    Clin Cancer Res; 2015 Oct 15; 21(20):4686-97. PubMed ID: 26124204
    [Abstract] [Full Text] [Related]

  • 9. Emerging treatment for advanced lung cancer with EGFR mutation.
    Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H.
    Expert Opin Emerg Drugs; 2015 Oct 15; 20(4):597-612. PubMed ID: 26153235
    [Abstract] [Full Text] [Related]

  • 10. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H, Azuma K, Sakai K, Kawahara A, Yamada K, Tokito T, Okamoto I, Nishio K, Hoshino T.
    Oncotarget; 2015 Oct 13; 6(31):30850-8. PubMed ID: 26334838
    [Abstract] [Full Text] [Related]

  • 11. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
    Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2009 Feb 01; 15(3):907-13. PubMed ID: 19188161
    [Abstract] [Full Text] [Related]

  • 12. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K, Murakami I, Sakai K, Mizuuchi H, Shimizu S, Sato K, Tomizawa K, Tomida S, Yatabe Y, Nishio K, Mitsudomi T.
    Sci Rep; 2015 Sep 24; 5():14447. PubMed ID: 26400668
    [Abstract] [Full Text] [Related]

  • 13. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation.
    Suda K, Mizuuchi H, Murakami I, Uramoto H, Tanaka F, Sato K, Takemoto T, Iwasaki T, Sekido Y, Yatabe Y, Mitsudomi T.
    Lung Cancer; 2014 Aug 24; 85(2):147-51. PubMed ID: 24939008
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
    Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.
    Anticancer Res; 2012 Sep 24; 32(9):3785-90. PubMed ID: 22993320
    [Abstract] [Full Text] [Related]

  • 15. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH, Soo RA.
    Drug Des Devel Ther; 2015 Sep 24; 9():5641-53. PubMed ID: 26508839
    [Abstract] [Full Text] [Related]

  • 16. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 24; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 17. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
    Sgambato A, Casaluce F, Maione P, Rossi A, Rossi E, Napolitano A, Palazzolo G, Bareschino MA, Schettino C, Sacco PC, Ciardiello F, Gridelli C.
    Curr Pharm Des; 2012 Feb 24; 18(37):6155-68. PubMed ID: 22873759
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
    Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L.
    Ann Oncol; 2018 Jan 01; 29(suppl_1):i10-i19. PubMed ID: 29462254
    [Abstract] [Full Text] [Related]

  • 19. The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Gou LY, Li AN, Yang JJ, Zhang XC, Su J, Yan HH, Xie Z, Lou NN, Liu SY, Dong ZY, Gao HF, Zhou Q, Zhong WZ, Xu CR, Wu YL.
    Oncotarget; 2016 Aug 09; 7(32):51311-51319. PubMed ID: 27259997
    [Abstract] [Full Text] [Related]

  • 20. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
    Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM.
    Oncotarget; 2016 Jul 26; 7(30):47998-48010. PubMed ID: 27384992
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 193.